Editas Medicine, Inc.2025财年第一财季实现净利润-76.09百万美元,同比减少22.82% 市场透视05/19 00:01 H.C. Wainwright维持Editas Medicine(EDIT.US)买入评级,维持目标价3美元 H.C. Wainwright分析师Mitchell Kapoor维持$Editas Medicine(EDIT.US)$买入评级,维持
EDIT Editas Medicine 添加自选 1.450 +0.060+4.32% 收盘价 05/09 16:00 (美东) 1.450 0.0000.00% 盘后17:34 (美东) 1.21亿总市值-0.50市盈率TTM 1.530最高价1.410最低价265.37万股成交量1.420今开1.390昨收386.65万成交额3.18%换手率亏损市盈率(静)8370.95万总股本6.69052周最高0.90市净率1.21亿流通值0.91052...
How Editas Medicine Could Make You Better (and Richer) If CRISPR therapies pan out, the possibilities are vast. Motley Fool Staff | Apr 9, 2019 Earnings Transcripts Editas Medicine, Inc (EDIT) Q3 2021 Earnings Call Transcript EDIT earnings call for the period ending September 30, 2021. ...
Get real-time Editas Medicine (0IFK) stock price quotes, analyst insights, forecasts, news, and information you need to help your stock trading and investing.
시가총액 93,763,000 주요 거래소 NASDAQ Editas Medicine Inc 실적 희석 주당 순이익(TTM) -2.88 전년 대비 매출 증가율 -49% 전년 대비 수익 증가율 0% 이익률 0%
Editas Medicine (EDIT) 1.3800 +0.1500 (+12.20%) 02/14/25 [NASDAQ] Barchart Opinion for Fri, Feb 14th, 2025 Tutorial Notes Alerts Watch Help You are viewing the Legacy Barchart Opinions. Click Here to view the Opinions page. Overall Average: 16% Sell Overall Average Signal calcula...
quotes Price Overview Performance Report charts Interactive Chart Snapshot Chart technicals Barchart Opinion Trading Strategies Top Trade Alerts Technical Analysis Trader's Cheat Sheet Seasonal Returns Price History Historical Data options Options Prices Volatility & Greeks Options Flow Options Time & Sales...
10 stocks we like better than Editas Medicine When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade,Motley Fool Stock Advisor, has tripled the market.* ...
Topics discussed include increase in stock market of biotechnology company Editas Medicine Inc. which offers genome editing technology, medical device Tandem Diabetes Care Inc. increases after its upgraded shares, decrease in Peregrine Pharmaceuticals Inc. after announcing it is discontinuing its trial of...
, we focus on analyzing editas stock price patterns and their correlations with different microeconomic environment and drivers. we also apply predictive analytics to build editas medicine's daily price indicators and compare them against related drivers, such as overlap studies and various other types...